-
241
Prevalence and factors associated with non-alcoholic fatty liver disease among women with polycystic ovary syndrome
Published 2025-01-01Subjects: “…Non-alcoholic fatty liver disease…”
Get full text
Article -
242
miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease—A New Diagnostic Path?
Published 2025-01-01“…Therefore, we decided to explore relationships between selected types of microRNAs (miRNAs), serological markers of liver fibrosis and hematological parameters in the course of non-alcoholic fatty liver disease (NAFLD). <b>Methods:</b> Two hundred and seven persons were included in the survey: 97 with NAFLD and 110 healthy controls. …”
Get full text
Article -
243
Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
Published 2018-09-01Subjects: “…nonalcoholic fatty liver disease…”
Get full text
Article -
244
-
245
Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease
Published 2020-01-01“…Gene expression profiles of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) were evaluated in peripheral blood leukocytes of children with nonalcoholic fatty liver disease (NAFLD). Gene expression patterns were correlated with their plasma protein counterparts, systemic parameters of liver injury, and selected markers of inflammation. …”
Get full text
Article -
246
Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD): Trends, Mortality, and Socioeconomic Disparities in the U.S., 1998–2020
Published 2025-01-01Subjects: “…fatty liver disease…”
Get full text
Article -
247
Association of leptin receptor Gln223Arg genetic polymorphism with obesity and non-alcoholic fatty liver disease
Published 2014-09-01Subjects: Get full text
Article -
248
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Published 2012-01-01“…Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. …”
Get full text
Article -
249
Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease
Published 2013-01-01“…There is growing evidence that white adipose tissue is an important contributor in the pathogenesis of alcoholic liver disease (ALD). We investigated serum concentrations of total adiponectin (Acrp30), leptin, and resistin in patients with chronic alcohol abuse and different grades of liver dysfunction, as well as ALD complications. …”
Get full text
Article -
250
Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin
Published 2020-01-01“…Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide with no curative therapy. …”
Get full text
Article -
251
Association between sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis
Published 2025-02-01“…Introduction: Considering that both long and short sleep duration may have an association with nonalcoholic fatty liver disease (NAFLD), in this meta-analysis, we analyzed the dose-response association between sleep duration and NAFLD along with meta-analyses of the differences in mean sleep duration between NAFLD patients and healthy controls, and linear meta-analysis of the association between sleep duration and NAFLD. …”
Get full text
Article -
252
Case Report: Cholestatic liver disease in the course of erythropoietic protoporphyria associated with renal hypodysplasia and atrial septal defect
Published 2025-02-01“…Progressive cholestatic liver disease (with subsequent congestive heart failure) was observed in the course of EPP. …”
Get full text
Article -
253
Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs
Published 2011-03-01“…According to actual data it was proved, that antibodies to cor-antigen of hepatitis B virus at patients with persistent hepatitis С virus infection do not alter biochemical activity and severity of liver disease. With application of prognostic models tendency to higher risk of end-stages of liver disease development at patients with persistent hepatitis B virus infection and anti-HBcor IgG in blood serum was revealed. …”
Get full text
Article -
254
Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients
Published 2018-01-01“…The significance of short-term changes in model for end-stage liver disease and Sodium (MELD-Na) following hepatocellular carcinoma (HCC) diagnosis is unknown. …”
Get full text
Article -
255
Effect of weight loss on the course of non-alcoholic fatty liver disease: results of 6-month follow-up
Published 2015-03-01Subjects: “…non-alcoholic fatty liver disease…”
Get full text
Article -
256
Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study
Published 2025-01-01Subjects: “…Non-alcoholic fatty liver disease…”
Get full text
Article -
257
Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Published 2025-01-01“…Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and affects nearly 30% of the adult population and 10% of the pediatric population. …”
Get full text
Article -
258
Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
Published 2015-12-01Subjects: “…direg 2, epidemiology, nafld, nonalcoholic fatty liver disease, nash, non-alcoholic steatohepatitis, prevalence…”
Get full text
Article -
259
-
260
Safety and recommendation of voriconazole for invasive pulmonary aspergillosis in severe liver disease patients: a retrospective cohort study
Published 2025-01-01Subjects: Get full text
Article